Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation

You may be able to join if

• Phase 2: Histologically confirmed diagnosis of NSCLC (squamous or nonsquamous) with KRAS G12C mutation and known PD-L1 TPS score and presence of measurable disease per RECIST v1.1.
• Phase 3: Histologically or cytologically confirmed diagnosis of unresectable or metastatic NSCLC (squamous or nonsquamous) with KRAS G12C mutation and PD-L1 ≥ 50% confirmed using Sponsor-approved testing (refer to laboratory manual for current list of Sponsor-approved tests).
• Phase 2 and 3: Presence of evaluable or measurable disease per RECIST version 1.1.
• Phase 3: CNS Inclusion–- Based on screening brain imaging, patients must have one of the following: 1. No evidence of brain metastases 2. Untreated asymptomatic brain metastases < 2.0 cm not needing immediate local therapy 3. Previously treated brain metastases not needing immediate local therapy .
• Phase 2 and Phase 3: Not a candidate for definitive therapy (eg, chemoradiation for locally advanced disease).
• Phase 3: A representative tumor specimen (primary or metastatic and newly obtained or archival sample must be available to be submitted to the Sponsor during screening or within 30 days of randomization.